Jawad M U, Extein J, Min E S, et al. Prognostic factors for survival in patients with epithelioid sarcoma: 441 cases from the SEER database[J]. Clin Orthop Relat Res,2009,467(11):2939-2948.
[2]
Le Loarer F, Zhang L, Fletcher C D, et al. Consistent SMARCB1 homozygous deletions in epithelioid sarcoma and in a subset of myoepithelial carcinomas can be reliably detected by FISH in archival material[J]. Genes Chromosomes Cancer,2014,53(6):475-486.
Sápi Z, Papp G, SzendrÖi M, et al. Epigenetic regulation of SMARCB1 by miR-206, -381 and -671-5p is evident in a variety of SMARCB1 immunonegative soft tissue sarcomas, while miR-765 appears specific for epithelioid sarcoma:a miRNA study of 223 soft tissue sarcomas[J]. Genes Chromosomes Cancer,2016,55(10):786-802.
[5]
Mukaihara K, Suehara Y, Kohsaka S, et al. Expression of F-actin-capping protein subunit beta, CAPZB, is associated with cell growth and motility in epithelioid sarcoma[J]. BMC Cancer,2016,16:206.
Saha D, Basu A, Maiti A, et al. Primary proximal epithelioid sarcoma of the lung successfully treated with pneumonectomy and adjuvant chemotherapy[J]. BMJ Case Rep,2016,21:3966.
[8]
Levy A, Le Péchoux C, Terrier P, et al. Epithelioid sarcoma: need for a multimodal approach to maximize the chances of curative conservative treatment[J].Ann Surg Oncol,2014, 21(1):269-276.
[9]
Jeon S Y, Yhim H Y, Lee N R. Epithelioid sarcoma with spontaneous pneumothorax and massive pleural effusion[J]. Korean J Intern Med,2016,31(1):191-193.
[10]
Choi S Y, Kim Y H, Kwon J B, et al. Epithelioid sarcoma metastatic to the lung as pulmonary cysts without other metastatic manifestation[J]. J Thorac Oncol,2008,3(5): 532-533.
Kato H, Hatori M, Watanabe M, et al. Epithelioid sarcoma with elevated serum CA125: report of two cases[J]. Jpn J Clin Oncol,2003,33(3):141-144.
[13]
Hoshino M, Kawashima H, Ogose A, et al. Serum CA 125 expression as a tumor marker for diagnosisand monitoring the clinical course of epithelioid sarcoma [J]. J Cancer Res Clin Oncol,2010,136(3):457-64.
[14]
Kohashi K, Yamada Y, Hotokebuchi Y, et al. ERG and SALL4 expressions in SMARCB1/INI1-deficient tumors: a useful tool for distinguishing epithelioid sarcoma from malignant rhabdoid tumor[J]. Hum Pathol,2015,46(2):225-230.
[15]
Jones R L, Constantinidou A, Olmos D, et al. Role of palliative chemotherapy in advanced epithelioid sarcoma[J]. Am J Clin Oncol,2012,35(4):351-357.
[16]
Pink D, Richter S, Gerdes S, et al. Gemcitabine and docetaxel for epithelioid sarcoma: results from a retrospective, multi-Institutional analysis[J]. Oncology, 2014,87(2):95-103.
[17]
Imura Y, Yasui H, Outani H, et al. Combined targeting of mTOR and c-MET signaling pathways for effective management of epithelioid sarcoma[J]. Mol Cancer,2014,13:185.
[18]
Xie X, Ghadimi M P, Young E D, et al. Combining EGFR and mTOR blockade for the treatment of epithelioid sarcoma[J]. Clin Cancer Res,2011,17(18):5901-5912.
[19]
Lopez G, Song Y, Lam R, et al. HDAC inhibition for the treatment of epithelioid sarcoma: novel cross talk between epigenetic components[J]. Mol Cancer Res,2016,14(1):35-43.
[20]
Irimura S, Nishimoto K, Kikuta K, et al. Successful treatment with pazopanib for multiple lung metastases of inguinal epithelioid sarcoma: a case report[J]. Oncol, 2015,8(3):378-384.
[21]
Asano N, Yoshida A, Ogura K, et al. Prognostic value of relevant clinicopathologic variables in epithelioid sarcoma: a multi-institutional retrospective study of 44 patients[J]. Ann Surg Oncol,2015,22(8):2624-2632.
2017, Vol. 28 
